Tags Archive Navigation
icon
-
Media ReleaseNovartis receives European Commission approval for Jakavi® to be the first post-steroid treatment for acute and chronic graft-versus-host disease
-
Media ReleaseNew Novartis data demonstrate only Kisqali® offers more life in the first-line setting for postmenopausal HR+/HER2- advanced breast cancer patients
-
Media ReleaseNovartis Kymriah® receives EC approval as first CAR-T cell therapy for adults with relapsed or refractory follicular lymphoma
-
Media ReleaseNovartis tislelizumab plus chemotherapy significantly improved overall survival as first-line treatment for advanced esophageal cancer in Phase III study
-
Media ReleaseNovartis receives positive CHMP opinion for Tabrecta® for patients with METex14 advanced non-small cell lung cancer
-
Media ReleaseNovartis announces early clinical data for unique KRASG12C inhibitor at American Association for Cancer Research annual meeting
-
Media ReleaseNovartis announces anti-PD-1 tislelizumab accepted by EMA for regulatory review in esophageal and lung cancers
-
Media ReleaseNovartis receives positive CHMP opinion for Jakavi® to treat acute and chronic graft-versus-host disease
-
Media ReleaseNovartis receives positive CHMP opinion for Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma in Europe
-
Media ReleaseNovartis Pluvicto™ approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA positive metastatic castration-resistant prostate cancer
-
Media ReleaseNovartis signs initial agreement with Carisma Therapeutics for the manufacturing of HER 2 targeted CAR-M cell therapy
-
Media ReleaseNEJM publication of Novartis Kisqali® data shows longest median overall survival ever reported in HR+/HER2- advanced breast cancer
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- …
- 9
- › Next page